(Q36905241)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Could we expect to improve survival in small cell lung cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Ghassan El Maalouf

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Jean-Michel Rodier

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Eric Raymond

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

57 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

S30-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Differences in lung cancer risk between men and women: examination of the evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Management of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Small cell lung cancer: state of the art and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Alkylating agents in bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970425-7

7 January 2021

10.1016/S0169-5002(07)70425-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17686444%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference